Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2009

View Archived Issues

AVI BioPharma reports efficacy data from phase Ib/II clinical trial of AVI-4658 in DMD

Forest Laboratories to acquire additional rights to NXL-104 under agreement with Novexel

Novel DNA-binding compounds presented by CSIR

GlaxoSmithKline describes nAChR modulators as antipsychotic agents

Mitsubishi Tanabe Pharma discloses novel BK and maxi K+ channel openers

Cathepsin C inhibitors for the treatment of COPD identified by GlaxoSmithKline

Lilly identifies CB1 ligands for the treatment of obesity

New data indicate ridaforolimus-trastuzumab beneficial in refractory metastatic breast cancer

Compugen discovers drug target for treatment of epithelial tumors

Sinovac Biotech files application with SFDA for clinical trial of HFMD vaccine

SemBioSys Genetics presents update of its progress on Apo AI(Milano)

Tego Biosciences sells intellectual property to Luna Innovations

BTC induces apoptosis in PKCalpha overexpressing breast cancer cells

Glycemic control enhanced by adding alogliptin to insulin therapy in type 2 diabetes

Breast cancer growth inhibition seen with JMR-132 and tamoxifen

MVA-BN-HER2 well tolerated, active in phase I breast cancer studies

Tetrathiomolybdate may reduce endothelial progenitor cells in breast cancer patients

EMEA issues negative opinion on Cerepro for malignant brain cancer

Affomix to provide antibodies for Kalgene's diagnostics program

LifeCycle submits phase III protocol for LCP-Tacro trial to the FDA

Vical's phase III trial of Allovectin-7 receives positive safety review

Vivus submits NDA for Qnexa to FDA for treatment of obesity

Arigene terminates tender offer for Trimeris' outstanding shares of common stock

GSK identifies 5-HT2B receptor antagonists for fibrotic conditions and IBS

Gilead describes SCD inhibitors for the treatment of obesity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...